Pulmonary fibrosis and interstitial lung disease (ILD) represent a heterogeneous group of over 200 diffuse parenchymal lung disorders characterized by inflammation and/or fibrosis of the lung interstitium — the scaffolding of connective tissue, alveolar epithelium, capillary endothelium, and supporting structures between the air sacs. The fibrotic ILDs — most critically Idiopathic Pulmonary Fibrosis (IPF) — carry a median survival of 3–5 years from diagnosis and remain among the most treatment-resistant conditions in medicine. Understanding the fibrotic cascade at the molecular level opens critical windows for both conventional antifibrotic intervention and integrative support targeting upstream drivers that conventional therapy does not address.
Classification: The ILD Spectrum
ILD is classified by underlying cause and histopathological pattern:
-
Idiopathic Interstitial Pneumonias (IIPs):
- Idiopathic Pulmonary Fibrosis (IPF) — UIP pattern; worst prognosis
- Nonspecific Interstitial Pneumonia (NSIP) — often autoimmune-associated; better prognosis
- Cryptogenic Organizing Pneumonia (COP) — steroid-responsive
- Acute Interstitial Pneumonia (AIP) — DAD pattern; rapidly fatal
- Respiratory Bronchiolitis-ILD (RB-ILD) — smoking-related
- Autoimmune/Connective Tissue Disease ILD: Rheumatoid arthritis-ILD, SSc-ILD (scleroderma), myositis-ILD (anti-MDA5, anti-Jo-1), Sjögren's-ILD, SLE-ILD, MCTD-ILD
- Hypersensitivity Pneumonitis (HP): Immune-mediated response to inhaled antigens — bird breeder's lung, farmer's lung, hot tub lung
- Occupational/Environmental ILD: Asbestosis, silicosis, coal workers' pneumoconiosis, berylliosis
- Drug-Induced ILD: Amiodarone, methotrexate, nitrofurantoin, bleomycin, checkpoint inhibitors
- Sarcoidosis: Granulomatous ILD with systemic involvement
- Progressive Pulmonary Fibrosis (PPF): Non-IPF ILDs demonstrating progressive fibrotic behavior
Pathophysiology: The Fibrotic Cascade
IPF pathogenesis is now understood as an aberrant wound healing response in the context of repetitive alveolar epithelial injury — not primarily an inflammatory disease (distinguishing it mechanistically from most ILD subtypes):
- Alveolar epithelial cell (AEC) injury: Repetitive microinjury from cigarette smoke, gastric microaspiration, viral infections (EBV, CMV, influenza), oxidative stress, and telomere attrition in genetically susceptible individuals (MUC5B promoter variant in ~35% of IPF patients)
- AEC senescence and ER stress: Injured Type II AECs enter senescence or undergo ER stress-induced apoptosis — failing to regenerate the alveolar epithelial surface. Senescent cells secrete a pro-fibrotic SASP (senescence-associated secretory phenotype): TGF-β1, PDGF, CTGF, IL-6, MMP-7
- TGF-β1-driven myofibroblast activation: TGF-β1 is the master pro-fibrotic cytokine — driving differentiation of fibroblasts and fibrocytes into myofibroblasts that deposit collagen I, III, and fibronectin, while resisting apoptosis (unlike normal wound-healing myofibroblasts)
- Pathological ECM remodeling: Excessive, cross-linked collagen matrix replaces functional alveoli — creating the "honeycombing" pattern on HRCT and reducing gas exchange capacity. MMP/TIMP imbalance favors collagen deposition over degradation
- Vascular remodeling: Loss of alveolar capillary bed reduces oxygen delivery; pulmonary hypertension develops in advanced IPF, dramatically worsening prognosis
In autoimmune ILD, the upstream driver is different — autoantibodies and autoreactive T cells target AECs and endothelial cells — but TGF-β1-driven fibrosis is the final common pathway shared across ILD subtypes.
Root Causes & Risk Factors
Genetic Predisposition
- MUC5B promoter variant (rs35705950): Present in ~35% of familial IPF and ~19% of sporadic IPF; increases MUC5B expression in distal airways, impairing mucociliary clearance and promoting AEC injury. Paradoxically associated with better survival despite higher incidence
- Telomere shortening genes: TERT, TERC, RTEL1, PARN mutations — drive AEC senescence by accelerating telomere attrition; associated with familial pulmonary fibrosis, aplastic anemia, and liver cirrhosis (telomere syndrome)
- SFTPC, SFTPB mutations: Surfactant protein mutations cause ER stress in Type II AECs, triggering the fibrotic cascade
Environmental Exposures
- Cigarette smoking: The strongest environmental risk factor for IPF — doubles risk; likely through oxidative AEC injury and telomere attrition acceleration
- Gastroesophageal reflux (GERD) and microaspiration: Strongly associated with IPF — microaspiration of gastric contents (acid, pepsin, bile acids) directly injures distal AECs. Prevalence of reflux in IPF patients exceeds 80%
- Occupational exposures: Metal dusts (steel, brass, lead), wood dusts, agricultural dusts, and silica all increase IPF risk independently of smoking
- Viral infections: EBV, CMV, and influenza have been found in IPF lung tissue; viral AEC injury may serve as repetitive trigger in genetically susceptible individuals
Autoimmune Drivers (in CTD-ILD)
Specific autoantibodies direct tissue injury in CTD-ILD: anti-Scl-70 (topoisomerase I) in SSc-ILD, anti-MDA5 in rapidly progressive myositis-ILD, anti-Jo-1 and anti-synthetase antibodies in antisynthetase syndrome, RF and anti-CCP in RA-ILD. Early identification and treatment of the underlying CTD is the primary determinant of ILD outcome in this category.
Diagnosis
- HRCT chest: The cornerstone — UIP pattern (basal-predominant, subpleural honeycombing ± traction bronchiectasis) is diagnostic for IPF when typical; NSIP pattern (ground-glass opacity, reticulation, traction bronchiectasis without honeycombing) suggests autoimmune ILD or HP
- PFTs: Restrictive pattern (reduced TLC, FVC, DLCO) with preserved or supranormal FEV1/FVC; DLCO reduction is the most sensitive marker of gas exchange impairment and tracks disease progression
- BAL (bronchoalveolar lavage): Lymphocytosis suggests HP or NSIP; neutrophilia + eosinophilia suggests IPF; markedly elevated lymphocytes (>25%) argues against IPF
- Surgical lung biopsy (VATS): Required when HRCT is atypical; histopathological UIP pattern confirmation
- Serological workup: ANA, RF, anti-CCP, anti-Scl-70, anti-centromere, Jo-1, MDA5, SSA/SSB, ANCA — exclude CTD-ILD before diagnosing IPF
- MDD (multidisciplinary discussion): Pulmonologist + radiologist + pathologist consensus is the diagnostic gold standard for IIP classification
Conventional Treatment
Antifibrotic Therapy (IPF-Specific)
- Nintedanib (Ofev): Triple tyrosine kinase inhibitor blocking PDGFR, VEGFR, and FGFR — all pro-fibrotic growth factor receptors. Reduces FVC decline rate by ~50% (INPULSIS trial, n=1,066). Also approved for SSc-ILD and PPF. Primary side effect: diarrhea (managed with loperamide, dose reduction); hepatotoxicity monitoring required. Reference: Richeldi L et al., NEJM, 2014.
- Pirfenidone (Esbriet): Pleiotropic antifibrotic — reduces TGF-β1, PDGF, and FGF activity; inhibits myofibroblast proliferation and collagen synthesis; antioxidant properties. Reduces FVC decline ~50% (CAPACITY/ASCEND trials). Primary side effects: photosensitivity, GI intolerance, fatigue. Reference: King TE et al., NEJM, 2014.
- Both drugs slow progression but do not reverse established fibrosis — establishing that intervention must begin early. Combination therapy trials are ongoing.
Immunosuppression (CTD-ILD, HP, NSIP)
- Mycophenolate mofetil (CellCept): First-line immunosuppression for SSc-ILD, myositis-ILD, and autoimmune NSIP — stabilizes FVC in multiple observational studies; SLS II trial confirmed similar efficacy to cyclophosphamide with better tolerability in SSc-ILD
- Azathioprine: Alternative steroid-sparing agent in CTD-ILD; better tolerated than cyclophosphamide
- Rituximab (anti-CD20): For refractory myositis-ILD and RA-ILD — depletes B cells producing pathogenic autoantibodies; emerging first-line use in anti-MDA5 rapidly progressive ILD
- Tocilizumab (anti-IL-6R): SSc-ILD — the focuSSced trial showed tocilizumab prevented FVC decline vs. placebo in anti-topoisomerase I positive SSc-ILD
- Prednisolone: High-dose for acute exacerbations of ILD and COP; low-dose maintenance for NSIP and HP. Avoid in IPF (AE-IPF–PANTHER trial showed harm with azathioprine/prednisolone/NAC combination)
Lung Transplantation
The only intervention that addresses established fibrosis — bilateral lung transplantation for IPF patients <65 with FVC <50%, DLCO <40%, or significant desaturation on 6MWT. 5-year survival post-transplant ~50% for IPF. Referral should occur early — IPF can deteriorate rapidly and patients may not survive the waitlist without timely referral.
Pulmonary Rehabilitation & Oxygen
PR improves exercise capacity, dyspnea, and quality of life in ILD. LTOT for resting or exertional hypoxia reduces mortality and improves exercise tolerance. Both are underutilized.
Repurposed Drugs with ILD Evidence
N-Acetylcysteine (NAC) — High-Dose
NAC 1,800mg/day directly replenishes alveolar glutathione — severely depleted in IPF lung tissue — and has direct antifibrotic properties (inhibits TGF-β1 signaling, reduces myofibroblast differentiation). The PANTHER-IPF trial found NAC alone (without azathioprine/prednisone) showed a non-significant trend toward benefit; post-hoc analyses of patients with TOLLIP rs3750920 TT genotype showed significant benefit. NAC is now used as adjunct to antifibrotic therapy. Reference: Martinez FJ et al., NEJM, 2014.
Proton Pump Inhibitors (GERD Management)
Given the strong association between microaspiration and IPF progression, aggressive GERD management with PPIs (± fundoplication in refractory cases) is a standard recommendation in IPF guidelines. Retrospective data suggests PPI use associates with slower FVC decline and reduced acute exacerbation risk in IPF.
Sildenafil (Pulmonary Hypertension Complication)
Pulmonary hypertension complicates advanced ILD in 30–40% of patients, dramatically worsening prognosis. Sildenafil (PDE5 inhibitor) reduces pulmonary vascular resistance and improves 6MWT and quality of life in ILD-associated PH — though the STEP-IPF trial in unselected IPF patients did not show primary endpoint benefit, significant quality-of-life improvements were observed.
Rapamycin (Sirolimus) — Senolytic Potential
mTORC1 inhibition by rapamycin suppresses AEC senescence (a primary driver of IPF pathogenesis) and reduces TGF-β1-driven myofibroblast activation in preclinical models. Phase I trials in IPF are ongoing. Of significant interest given that IPF is increasingly recognized as a disease of accelerated cellular aging.
Vitamins, Supplements & Compounds
N-Acetylcysteine (NAC)
As above — dose for ILD adjunct therapy: 600mg three times daily (1,800mg/day). Produces clinically meaningful glutathione repletion in alveolar epithelial lining fluid, directly countering the severe oxidative stress driving AEC injury and senescence. Safe to combine with nintedanib or pirfenidone.
Vitamin D
Vitamin D deficiency is highly prevalent in ILD patients and correlates with worse FVC and DLCO. Vitamin D inhibits TGF-β1-driven myofibroblast differentiation, reduces fibroblast proliferation, and promotes epithelial repair through VDR-mediated gene expression. In SSc-ILD specifically, vitamin D levels inversely correlate with skin fibrosis score and ILD severity. Dose: 5,000–8,000 IU/day; target 60–80 ng/mL. Reference: Gupta N et al., Lung India, 2016.
Quercetin (Senolytic Activity)
Quercetin combined with dasatinib (D+Q) is the most clinically studied senolytic combination — selectively clearing senescent cells that drive the IPF fibrotic cascade via SASP. A pilot clinical trial (Justice JN et al., EBioMedicine, 2019) demonstrated that 3-week D+Q treatment in IPF patients significantly improved physical function (6MWT, gait speed, chair stands) — the first clinical evidence that senolytic therapy is feasible and potentially beneficial in IPF. Quercetin alone has also demonstrated antifibrotic effects via Nrf2 activation and TGF-β1 pathway suppression. Dose: quercetin 1,000mg with dasatinib (requires physician prescription); quercetin alone 500–1,000mg daily. Reference: Justice JN et al., EBioMedicine, 2019.
Omega-3 Fatty Acids
EPA-derived resolvin E1 and DHA-derived protectin D1 promote resolution of lung inflammation and inhibit TGF-β1-driven fibroblast activation. Omega-3 supplementation reduces inflammatory markers and may slow fibrotic progression when combined with antifibrotic therapy. Also addresses cardiovascular comorbidity universal in ILD patients. Dose: 3–4g EPA+DHA daily.
Astaxanthin
A carotenoid antioxidant with 550× greater singlet oxygen quenching capacity than vitamin E and 6,000× greater than vitamin C — directly scavenges the ROS driving AEC injury in IPF. Also inhibits NF-κB and TGF-β1 signaling in lung fibroblasts in animal models. Lipophilic — take with fat. Dose: 8–12mg daily.
Magnesium
Required cofactor for glutathione synthetase (GSH production) and over 300 antioxidant/repair enzymes. Hypomagnesemia is common in ILD patients on PPIs (which impair Mg absorption). Replete before expecting full NAC/GSH benefit. Dose: 300–400mg elemental magnesium glycinate nightly.
Coenzyme Q10 (Ubiquinol)
Mitochondrial dysfunction and oxidative stress in AECs are primary drivers of cellular senescence in IPF. Ubiquinol supports mitochondrial respiratory chain function and reduces mitochondrial ROS generation — directly targeting the upstream driver of AEC senescence. Dose: 200–300mg ubiquinol daily. Cross-reference: CoQ10 & PQQ: Mitochondrial Energy, Cellular Repair & Longevity.
PQQ (Pyrroloquinoline Quinone)
Stimulates mitochondrial biogenesis via PGC-1α — potentially reversing the mitochondrial dysfunction driving AEC senescence in IPF. Also reduces oxidative stress in lung epithelial cells. Dose: 20mg daily with CoQ10.
Fisetin
A flavonol with emerging senolytic activity — fisetin selectively eliminates senescent cells by inducing apoptosis through BCL-2/BCL-xL inhibition while sparing healthy cells. Preclinical data in lung fibrosis models is compelling; human trials ongoing. Dose: 100–500mg daily (high-bioavailability form preferred; standard fisetin has poor oral bioavailability).
Botanical Treatments
Curcumin
One of the most extensively studied botanical antifibrotics — curcumin inhibits TGF-β1/Smad signaling (the primary fibrotic pathway), suppresses NF-κB-driven inflammatory cytokines, activates Nrf2 antioxidant response, and directly inhibits myofibroblast differentiation and collagen synthesis. Animal models of bleomycin-induced pulmonary fibrosis consistently show curcumin reduces fibrosis severity, even when initiated after fibrosis has begun. Use bioavailable formulation. Dose: 500–1,500mg BCM-95 or phytosome curcumin daily. Reference: Punithavathi D et al., J Pharmacol Exp Ther, 2000.
Berberine
Activates AMPK, which directly inhibits mTOR — the same pathway targeted by rapamycin for its senolytic/antifibrotic effects. Berberine also inhibits TGF-β1 signaling, reduces myofibroblast α-SMA expression, and suppresses EMT (epithelial-mesenchymal transition) in AECs — a proposed mechanism of fibroblast pool expansion in IPF. Additionally modulates gut microbiome composition relevant to systemic inflammation. Dose: 500mg twice daily with meals. Reference: Wu H et al., Respir Res, 2020.
Resveratrol
Activates SIRT1 (sirtuin 1), which deacetylates and activates FOXO transcription factors and p53 — promoting senescent cell clearance and reducing SASP production. Also inhibits TGF-β1 and reduces pulmonary fibrosis in animal models. Bioavailability is a significant clinical challenge — use trans-resveratrol with piperine or liposomal formulations. Dose: 250–500mg trans-resveratrol daily. Cross-reference: Supplements & Compounds Hub.
Boswellia (AKBA)
AKBA inhibits 5-LOX and NF-κB, reducing the inflammatory component of ILD progression. Particularly relevant in HP and autoimmune ILD where inflammatory drive is primary. Also reduces VEGF-driven angiogenesis that supports fibrotic lesion expansion. Dose: 300–400mg AKBA-standardized extract 3× daily.
Andrographis
Andrographolide inhibits TGF-β1/Smad3 signaling in lung fibroblasts — reducing myofibroblast differentiation and collagen I synthesis in animal pulmonary fibrosis models. Also reduces viral trigger burden (rhinovirus, influenza) that precipitate acute ILD exacerbations. Dose: 200–400mg andrographolide-standardized extract during respiratory infections; 100mg daily maintenance.
Astragalus (Astragalus membranaceus)
Astragaloside IV activates telomerase (via TA-65/hTERT pathway) — directly addressing the telomere shortening that drives AEC senescence in familial and sporadic IPF. The most compelling botanical intervention targeting the genetic root cause of IPF. Also immunomodulatory and anti-inflammatory. Dose: 250–500mg astragaloside IV-standardized extract daily.
Integrative Protocol Summary
Foundation (All ILD Patients)
- Optimize antifibrotic or immunosuppressive therapy with pulmonologist
- Aggressive GERD management (dietary + PPI ± fundoplication)
- Smoking cessation — absolute requirement
- NAC: 600mg 3× daily (1,800mg/day)
- Vitamin D: 5,000–8,000 IU/day (target 60–80 ng/mL)
- Omega-3: 3–4g EPA+DHA daily
- Ubiquinol: 200–300mg daily
- Magnesium glycinate: 300–400mg elemental nightly
IPF-Specific (Antifibrotic + Antifibrotic)
- Curcumin (BCM-95): 1,000–1,500mg daily
- Berberine: 500mg twice daily
- Astragalus (astragaloside IV): 250–500mg daily (telomerase activation)
- Quercetin: 1,000mg daily (senolytic + antifibrotic)
- Fisetin: 100–300mg daily
- PQQ: 20mg daily (mitochondrial biogenesis)
CTD-ILD / Autoimmune ILD
- Boswellia (AKBA): 300mg 3× daily
- Omega-3: 3–4g daily (immune modulation + SPM production)
- Vitamin D: optimize (immunomodulatory, anti-fibrotic)
- Resveratrol: 250–500mg trans-resveratrol daily
- Do not discontinue immunosuppression — botanicals are adjuncts
Key Citations
- Richeldi L et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
- King TE et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019;40:554-563.
- Martinez FJ et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis (PANTHER-IPF). N Engl J Med. 2014;370(22):2093-2101.
- Punithavathi D et al. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. J Pharmacol Exp Ther. 2000;295(3):1093-1095.
- Wu H et al. Berberine inhibits the progression of pulmonary fibrosis. Respir Res. 2020.
0 comments